Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 1
2003 1
2005 2
2006 1
2007 3
2008 8
2009 6
2010 4
2011 1
2012 3
2013 4
2014 4
2015 8
2016 9
2017 3
2018 9
2019 5
2020 11
2021 7
2022 0
Text availability
Article attribute
Article type
Publication date

Search Results

80 results
Results by year
Filters applied: . Clear all
Page 1
PP2A inhibition is a druggable MEK inhibitor resistance mechanism in KRAS-mutant lung cancer cells.
Kauko O, O'Connor CM, Kulesskiy E, Sangodkar J, Aakula A, Izadmehr S, Yetukuri L, Yadav B, Padzik A, Laajala TD, Haapaniemi P, Momeny M, Varila T, Ohlmeyer M, Aittokallio T, Wennerberg K, Narla G, Westermarck J. Kauko O, et al. Among authors: westermarck j. Sci Transl Med. 2018 Jul 18;10(450):eaaq1093. doi: 10.1126/scitranslmed.aaq1093. Sci Transl Med. 2018. PMID: 30021885 Free PMC article.
Druggable cancer phosphatases.
Vainonen JP, Momeny M, Westermarck J. Vainonen JP, et al. Among authors: westermarck j. Sci Transl Med. 2021 Apr 7;13(588):eabe2967. doi: 10.1126/scitranslmed.abe2967. Sci Transl Med. 2021. PMID: 33827975 Review.
Cancer stem cell phosphatases.
Momeny M, Arsiola T, Westermarck J. Momeny M, et al. Among authors: westermarck j. Biochem J. 2021 Jul 30;478(14):2899-2920. doi: 10.1042/BCJ20210254. Biochem J. 2021. PMID: 34319405 Review.
Mechanisms of MYC stabilization in human malignancies.
Junttila MR, Westermarck J. Junttila MR, et al. Among authors: westermarck j. Cell Cycle. 2008 Mar 1;7(5):592-6. doi: 10.4161/cc.7.5.5492. Epub 2007 Dec 29. Cell Cycle. 2008. PMID: 18256542 Review.
80 results